Our data clearly indicates that mahanine treatment causes a decline in the levels of DNMT1 and DNMT3B, without affecting the levels of DNMT3A, in both LNCaP and PC3 prostate cancer cells. This evidence concerns the gene DNMT3A and prostate cancer.